Ablation for lung spots in advanced liver cancer patients
Looks at lung spot ablation with drug therapy in advanced liver cancer.
Plain-language title generated from the registry record
Registry title: Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced liver cancer (hepatocellular carcinoma) that has spread to the lungs in a small number of spots, and who have already had systemic treatment.
- Age
- 18 to 80 years in the registry fields; the exclusion list says under 18 or over 75 years cannot join.
- Sex
- All sexes can join.
- Disease stage
- Primary or recurrent hepatocellular carcinoma (HCC) with a few spots in the lung. No more than five metastases, in no more than two organs, each at most 5cm (2 in) across. Intermediate HCC is not accepted.
- Earlier treatment
- First-line systemic therapy for at least 3 months before ablation, with a response to it. Liver-directed treatment such as TACE or HAIC is also described.
Main reasons for not taking part
- Intermediate HCC
- More than five metastases
- No response to systemic therapy
- Metastases larger than 5 cm (2 in)
- Life expectancy less than 3 months
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06644430, who can take part
Where in China
- Chinese PLA General HospitalBeijing, ChinaContact: Qunfang Zhou, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT06644430
- Record updated
- 23 October 2026
- Original description
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.Read full original descriptionShow less
Ablation of Pulmonary Oligometastasis Combined With System Compared System Therapy for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.
Inclusion: diagnosis of primary or recurrent HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases; presence of pulmonary oligometastasis; metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm; receipt of first-line systemic therapy for minimum of 3 months before ablation; undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) were included; classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; no history of other malignancies; life expectancy more than 3 months; agreed to participated in this clinical trial; Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.
Exclusion: no response to systemic therapy; age < 18 years or > 75 years; intermediate HCC; advanced HCC with more than five metastases; metastases size > 5 cm; life expectancy less than 3 months.